Clene Inc. shares fall 3.47% in premarket after recent 5-day surge of 68.78%.

Clene Inc. fell 3.47% in premarket trading, as the clinical-stage pharmaceutical company focuses on developing its Clean Surface Nanotechnology (CSN®) drug treatments for central nervous system diseases, including ALS, MS, and Parkinson's disease. The company's electrocrystallization drug development platform enables the production of concentrated, stable, and highly active clean surface nanocrystal suspensions, supporting the development of its drug assets. The stock has surged 68.78% over the past five days, indicating strong market interest in its technology and products.